Insilico Medicine Nominates Potential First-in-Class Preclinical Candidate with Novel AI-Designed Structure for Novel AI-Discovered Target in Immuno-oncology
20 déc. 2022 09h00 HE
|
InSilico Medicine
New York, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company...
Sosei Heptares to present at 41st Annual J.P. Morgan Healthcare Conference
20 déc. 2022 01h30 HE
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) announces its President & CEO Chris Cargill will present at the 41st...
Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder
18 déc. 2022 19h34 HE
|
Bionomics Ltd
BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary EndpointSubjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to...
Persbericht Biocartis Group NV: Voltooiing van verplichte conversie
16 déc. 2022 11h40 HE
|
Biocartis NV
PERSBERICHT: GEREGLEMENTEERDE INFORMATIE16 december 2022, 17:40 CET Voltooiing van Verplichte Conversie Bepalingen met een hoofdletter in deze kennisgeving die niet werden gedefinieerd zullen de...
Press release Biocartis Group NV: Completion of Mandatory Conversion
16 déc. 2022 11h40 HE
|
Biocartis NV
PRESS RELEASE: REGULATED INFORMATION16 December 2022, 17:40 CET Completion of Mandatory Conversion Capitalized terms not otherwise defined in this notice shall have the meaning given to them in the...
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
16 déc. 2022 06h30 HE
|
Ocugen
MALVERN, Pa., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases
15 déc. 2022 19h01 HE
|
Sosei Group Corporation
New agreement leverages Sosei Heptares’ GPCR-focused structure-based drug design capabilities and Lilly’s extensive development, commercialization and therapeutic area expertiseSosei Heptares eligible...
Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer
15 déc. 2022 18h35 HE
|
Bionomics Ltd
ADELAIDE, Australia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric...
Barbara D. Stinnett Joins Boon Logic’s Board of Directors
15 déc. 2022 16h26 HE
|
Boon Logic
MINNEAPOLIS, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Boon Logic, provider of the world’s fastest AI-based anomaly detection solutions, today announced the appointment of Barbara D. Stinnett to its board...
First Light Acquisition Group, Inc. Announces Approval of Extension Amendment to Certificate of Incorporation
15 déc. 2022 10h59 HE
|
First Light Acquisition Group
NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE: FLAG) (“FLAG”) today announced that its Board of Directors approved an extension of the date by which it has to...